Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

Allergan

Status: Completed

Conditions: Macular Oedema; Retinal Vein Occlusion

Treatments: Drug: dexamethasone intravitreal implant 0.7 mg

Study type: Observational

Funder types: Industry

Identifiers

NCT01566526

MAF/AGN/OPH/RET/012

Details and patient eligibility

About

The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.

Enrollment: 26 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular oedema in at least one eye due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
• Received at least two OZURDEX® injections in the study eye as part of the Belgium Medical Needs Program

Exclusion criteria

• None

Trial design

26 participants in 1 patient group

Patients Previously Treated with OZURDEX®

Description:

OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.

Treatment:

Drug: dexamethasone intravitreal implant 0.7 mg